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A bs tr ac t
Background
Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been 
shown to reduce rates of bleeding and death in patients undergoing primary percu-
taneous coronary intervention (PCI). Whether these benefits persist in contempo-
rary practice characterized by prehospital initiation of treatment, optional use of 
glycoprotein IIb/IIIa inhibitors and novel P2Y12 inhibitors, and radial-artery PCI 
access use is unknown.
Methods
We randomly assigned 2218 patients with ST-segment elevation myocardial infarc-
tion (STEMI) who were being transported for primary PCI to receive either bivaliru-
din or unfractionated or low-molecular-weight heparin with optional glycoprotein 
IIb/IIIa inhibitors (control group). The primary outcome at 30 days was a composite 
of death or major bleeding not associated with coronary-artery bypass grafting 
(CABG), and the principal secondary outcome was a composite of death, reinfarc-
tion, or non-CABG major bleeding.
Results
Bivalirudin, as compared with the control intervention, reduced the risk of the pri-
mary outcome (5.1% vs. 8.5%; relative risk, 0.60; 95% confidence interval [CI], 0.43 
to 0.82; P = 0.001) and the principal secondary outcome (6.6% vs. 9.2%; relative risk, 
0.72; 95% CI, 0.54 to 0.96; P = 0.02). Bivalirudin also reduced the risk of major 
bleeding (2.6% vs. 6.0%; relative risk, 0.43; 95% CI, 0.28 to 0.66; P<0.001). The risk 
of acute stent thrombosis was higher with bivalirudin (1.1% vs. 0.2%; relative risk, 
6.11; 95% CI, 1.37 to 27.24; P = 0.007). There was no significant difference in rates 
of death (2.9% vs. 3.1%) or reinfarction (1.7% vs. 0.9%). Results were consistent 
across subgroups of patients.
Conclusions
Bivalirudin, started during transport for primary PCI, improved 30-day clinical 
outcomes with a reduction in major bleeding but with an increase in acute stent 
thrombosis. (Funded by the Medicines Company; EUROMAX ClinicalTrials.gov 
number, NCT01087723.)
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Primary percutaneous coronary in-tervention (PCI), which is the standard of care for the treatment of patients with ST- 
segment elevation myocardial infarction (STEMI),1,2 
requires adjunctive antithrombotic treatment 
with anticoagulants and antiplatelet agents. In 
the Harmonizing Outcomes with Revasculariza-
tion and Stents in Acute Myocardial Infarction 
(HORIZONS-AMI) trial,3 bivalirudin (Angiomax, 
Angiox, the Medicines Company), as compared 
with unfractionated heparin and routine use of 
glycoprotein IIb/IIIa inhibitors, reduced rates of 
major bleeding and death at 30 days, with a sur-
vival benefit that extended to 3 years,4 albeit with 
an increased rate of acute stent thrombosis.
A number of changes have occurred in clini-
cal practice since the HORIZONS-AMI trial was 
conducted: the use of radial-artery PCI access, 
which may reduce the risk of bleeding and vas-
cular complications,5 has expanded; and the use 
of ticagrelor or prasugrel has been increasingly 
adopted.6,7 In parallel, the use of glycoprotein 
IIb/IIIa inhibitors has declined and is no longer 
routine. Anticoagulation is frequently started 
early, either because the patient presents at a 
hospital where PCI is not performed and thus 
requires transport to another hospital or — as is 
frequently the case in Europe — because treat-
ment is started in the ambulance.
The European Ambulance Acute Coronary 
Syndrome Angiography (EUROMAX) trial, an in-
ternational, randomized, open-label study, was 
designed to test whether bivalirudin, initiated dur-
ing transport for primary PCI in patients with 
STEMI, was superior to heparins with optional 
use of glycoprotein IIb/IIIa inhibitors in contem-
porary practice, with frequent use of radial ac-
cess and novel P2Y12 inhibitors.8
Me thods
Study Design
The trial was designed by an academic executive 
committee (see the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org) and the sponsor (the Medicines Company), 
with the latter collecting the data. An academic 
statistical group received data from the sponsor 
and provided data and analyses to the indepen-
dent data and safety monitoring committee. At 
trial completion, data were analyzed by the spon-
sor and validated by an independent academic 
statistical group led by two of the authors that 
had the full data set.
The first author wrote the first draft of the 
manuscript, which was revised and approved by 
all coauthors, and provided for comment to the 
sponsor. Editorial support (limited to editing for 
style, referencing, and use of graphics) was pro-
vided by MedLink Healthcare Communications 
and was funded by the Medicines Company. The 
authors made the decision to submit the manu-
script for publication; they accept full responsibil-
ity for the accuracy and completeness of the data 
and all analyses and for the fidelity of this report 
to the trial protocol, available at NEJM.org.
Study Patients
The study enrolled men and nonpregnant women 
(18 years of age or older) presenting within 12 
hours after the onset of symptoms with a pre-
sumed diagnosis of STEMI, with any of the fol-
lowing conditions: ST-segment elevation of at 
least 1 mm in two contiguous leads on electro-
cardiography, presumed new left bundle-branch 
block, or ST-segment depression of at least 1 mm 
in at least two leads in V1 through V3 with a pos-
itive terminal T wave. All patients had to be 
scheduled for angiography with the intention of 
performing primary PCI within 2 hours after the 
first medical contact. The main exclusion criteria 
were treatment with any injectable anticoagulant 
before randomization, oral anticoagulation, re-
cent surgery, and a history of bleeding. A full set 
of inclusion and exclusion criteria is provided in 
the Supplementary Appendix.
Patients were identified, initial consent was 
obtained, randomization was performed, and 
study-drug administration was initiated in the 
ambulance or in a non-PCI hospital. Patients were 
transported urgently to the primary PCI hospital, 
where treatment was continued and outcomes 
data collected. All patients initially provided 
abridged written or oral informed consent in the 
ambulance or non-PCI hospital before study-drug 
administration. This consent was subsequently 
confirmed by a more formal final written in-
formed consent. The study was approved by local 
ethics committees and health authorities.8
Study Treatments
Patients who were assigned to the bivalirudin 
group received a bolus of 0.75 mg per kilo-
gram of body weight, followed by an infusion of 
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1.75 mg per kilogram per hour. The protocol 
specified that the infusion should be continued 
for at least 4 hours after PCI. The protocol also 
specified that the dose during the post-PCI inter-
val should be 0.25 mg per kilogram per hour; 
however, continuation of the higher dose used 
during PCI was also permitted. Bailout use of a 
glycoprotein IIb/IIIa inhibitor was allowed in the 
event of giant thrombus or microvascular ob-
struction (no reflow).
Patients who were assigned to the heparin 
group (control group) received either unfraction-
ated heparin (100 IU per kilogram without a 
glycoprotein IIb/IIIa inhibitor or 60 IU per kilo-
gram with a glycoprotein IIb/IIIa inhibitor) or an 
intravenous bolus of enoxaparin (0.5 mg per ki-
logram). The use of glycoprotein IIb/IIIa inhibi-
tors was left to physician preference and was 
categorized as either routine (started before PCI) 
or bailout. Any glycoprotein IIb/IIIa inhibitor could 
be used at the approved doses and regimens.
All patients received aspirin and an approved 
P2Y12 inhibitor as early as possible after the first 
medical contact. Decisions regarding access site, 
performance of thrombus aspiration, and stent 
type were left to physician preference.
Study Outcomes
The primary outcome was a composite of death 
from any cause or major bleeding not related to 
coronary-artery bypass grafting (CABG) at 30 
days. The principal secondary 30-day outcome 
was a composite of death from any cause, rein-
farction, or non-CABG major bleeding. Other 
secondary end points included major adverse car-
diovascular events (death, reinfarction, ischemia-
driven revascularization, or stroke), net adverse 
clinical events (composite of major adverse car-
diovascular events and non-CABG major bleed-
ing), each of the components of the primary and 
principal secondary outcomes, ischemia-driven 
revascularization, stent thrombosis (as defined 
by the Academic Research Consortium9), and a 
composite of reinfarction, ischemia-driven revas-
cularization, or stent thrombosis.
The protocol definition of major bleeding was 
bleeding unrelated to CABG surgery that in-
cluded intracranial, retroperitoneal, or intraocu-
lar bleeding; access-site hemorrhage requiring 
radiologic or surgical intervention; a reduction 
in the hemoglobin level of more than 4 g per 
deciliter (2.5 mmol per liter) without an overt 
source of bleeding; a reduction in the hemoglo-
bin level of more than 3 g per deciliter (1.8 mmol 
per liter) with an overt source of bleeding; reinter-
vention for bleeding; or use of any blood-product 
transfusion. Bleeding was also assessed accord-
ing to Thrombolysis in Myocardial Infarction 
(TIMI)10 and Global Utilization of Streptokinase 
and Tissue Plasminogen Activator for Occluded 
Coronary Arteries (GUSTO)11 criteria.
Table 1. Baseline Characteristics of the Intention-to-Treat Population.*
Characteristic
Bivalirudin  
(N = 1089)
Control  
(N = 1109)
Age
Median (IQR) — yr 61 (52–71) 62 (52–72)
>65 yr — no. (%) 394 (36.2) 434 (39.1)
Female sex — no. (%) 275 (25.3) 248 (22.4)
Cardiac-related history — no. (%)†
Diabetes‡ 127 (11.7) 169 (15.3)
Hypertension 459 (42.2) 504 (45.5)
Hyperlipidemia§ 398 (36.6) 417 (37.6)
Current smoker 453 (41.6) 472 (42.6)
Previous myocardial infarction‡ 80 (7.4) 113 (10.2)
Previous percutaneous coronary 
intervention
97 (8.9) 108 (9.7)
Previous CABG 18 (1.7) 29 (2.6)
Killip class II, III, or IV — no./total no. (%)¶ 77/996 (7.7) 69/1000 (6.9)
Anemia — no./total no. (%) 129/987 (13.1) 148/989 (15.0)
Creatinine clearance — no./total no. (%)
≤60 ml/min 147/1001 (14.7) 165/998 (16.5)
>60 ml/min 854/1001 (85.3) 833/998 (83.5)
Country — no. (%)
France 398 (36.5) 397 (35.8)
Netherlands 377 (34.6) 391 (35.3)
Germany 139 (12.8) 140 (12.6)
Denmark 78 (7.2) 72 (6.5)
Other‖ 97 (8.9) 109 (9.8)
* There were no significant between-group differences except in the two catego-
ries that are noted below. CABG denotes coronary-artery bypass grafting, and 
IQR interquartile range.
† Data on cardiac-related history were missing for one patient in each study 
group.
‡ P<0.05 for the between-group comparison.
§ Hyperlipidemia was defined as a diagnosis of hyperlipidemia or the use of 
 lipid-lowering therapy.
¶ Killip classes are as follows: class I, no clinical signs of heart failure; class II, 
rales or crackles in the lungs, a third heart sound, and an elevated jugular ve-
nous pressure; class III, frank acute pulmonary edema; and class IV, cardio-
genic shock or hypotension and evidence of peripheral vasoconstriction.
‖ Other countries include Austria, Czech Republic, Italy, Poland, and Slovenia.
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Table 2. Procedures and Study Medications in the Intention-to-Treat Population.*
Variable Bivalirudin (N = 1089) Control (N = 1109)
Randomized in ambulance — no. (%) 1030 (94.6) 1045 (94.2)
Randomized in non–PCI-capable hospital — no. (%)  59 (5.4)  64 (5.8)
Aspirin use — no. (%)  1088 (100.0)   1107 (99.8)
P2Y12 inhibitor loading dose — no./total no. (%)
Any agent 1048/1066 (98.3) 1058/1083 (97.7)
Clopidogrel  524/1048 (50.0)  545/1058 (51.5)
Ticlopidine 0   2/1058 (0.2)
Prasugrel  323/1048 (30.8)  306/1058 (28.9)
Ticagrelor  201/1048 (19.2)  205/1058 (19.4)
P2Y12 loading dose before angiography — no./total no. (%)  913/1011 (90.3)  923/1010 (91.4)
P2Y12 inhibitor maintenance dose — no./total no. (%)
Any agent  957/1065 (89.9)  969/1082 (89.6)
Clopidogrel   377/957 (39.4)   407/969 (42.0)
Ticlopidine    2/957 (0.2)    5/969 (0.5)
Prasugrel   321/957 (33.5)   298/969 (30.8)
Ticagrelor   257/957 (26.9)   259/969 (26.7)
Initial anticoagulation — no. (%)
Bivalirudin 1074 (98.6) 29 (2.6)
Unfractionated heparin  24 (2.2) 997 (89.9)
Enoxaparin 0 94 (8.5)
Median time from initiation of anticoagulation to angiography (IQR) 
— min
    50 (37−67)    50 (37−65)
Glycoprotein IIb/IIIa inhibitor — no./total no. (%)†
Any 125/1088 (11.5)  766/1109 (69.1)
Routine use  42/1088 (3.9)‡  649/1109 (58.5)
Bailout use§ 83/1046 (7.9)   117/460 (25.4)
Arterial-access site — no./total no. (%)
Femoral 558/1069 (52.2)  582/1084 (53.7)
Radial 510/1069 (47.7)  502/1084 (46.3)
Single-vessel disease — no./total no. (%) 591/1069 (55.3)  556/1083 (51.3)
Left-main-stem disease — no./total no. (%) 82/1069 (7.7)  86/1084 (7.9)
Infarct artery treated with primary PCI — no./total no. (%)
Left main coronary artery   6/943 (0.6)   13/946 (1.4)
Left anterior descending coronary artery  425/943 (45.1)   423/946 (44.7)
Left circumflex coronary artery  115/943 (12.2)   132/946 (14.0)
Right coronary artery  417/943 (44.2)   412/946 (43.6)
Bypass grafting (venous or arterial)   4/943 (0.4)   10/946 (1.1)
Balloon angioplasty only — no./total no. (%)  48/943 (5.1)   42/946 (4.4)
Implantation of stent — no./total no. (%)
Any type  868/943 (92.0)   865/946 (91.4)
Drug-eluting  538/943 (57.1)   529/946 (55.9)
Thrombectomy — no./total no. (%)  304/943 (32.2)   298/946 (31.5)
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The primary study outcome was changed dur-
ing the course of the trial. The original primary 
outcome measure was the composite of death from 
any cause, reinfarction, or non-CABG major bleed-
ing, which became the principal secondary out-
come after the change in the protocol. The change 
in the primary outcome was made in order to re-
duce the necessary sample size and occurred while 
the investigators were still unaware of study out-
comes. Details of the circumstances surrounding 
the change in the primary outcome are provided in 
the Supplementary Appendix.
An independent clinical-events committee 
whose members were unaware of study-group 
assignments adjudicated deaths, bleeding epi-
sodes, reinfarction, ischemia-driven revascular-
ization, stent thrombosis, and stroke.8 Detailed 
definitions of all study end points are provided 
in the Supplementary Appendix.
Statistical Analysis
We determined that a sample size of 2200 pa-
tients would provide a power of 80% for deter-
mining the primary outcome at a two-sided al-
pha level of 0.05, assuming an event rate of 4.25% 
in the bivalirudin group and 7.0% in the control 
group. One planned interim analysis was per-
formed by an independent statistician, after 
which the data and safety monitoring committee 
recommended that the trial continue as planned 
(see the Supplementary Appendix for details).
Analyses were performed in the intention-to-
treat population, which was defined as all pa-
tients who underwent randomization and pro-
vided written informed consent. We used the 
chi-square test to perform comparisons of event 
rates or Fisher’s exact test in the case of sparse 
data. We used the log-rank test to compute the 
significance of time-to-event data. Continuous 
variables are reported as medians and interquar-
tile ranges. Categorical variables are reported as 
frequencies and percentages. Analyses were per-
formed with the use of SAS software, version 9.2.
R esult s
Patients
A total of 2218 patients were enrolled in the trial 
from 65 sites in nine European countries from 
March 10, 2010, through June 20, 2013 (Fig. S1 in 
Table 2. (Continued.)
Variable Bivalirudin (N = 1089) Control (N = 1109)
TIMI flow — no./total no. (%)
Before PCI
0 to 1 593/931 (63.7) 563/932 (60.4)
2 143/931 (15.4) 158/932 (17.0)
3 195/931 (20.9) 211/932 (22.6)
After PCI
0 or 1 18/930 (1.9) 16/932 (1.7)
2 29/930 (3.1) 31/932 (3.3)
3 883/930 (94.9) 885/932 (95.0)
CABG during hospitalization — no. (%)  21 (1.9)  29 (2.6)
Medications at discharge — no. (%)
ACE inhibitor or ARB  718 (65.9)  709 (63.9)
Aspirin 1000 (91.8) 1012 (91.3)
Beta-blocker  944 (86.7)  957 (86.3)
P2Y12 inhibitor  938 (86.1)  941 (84.9)
Statin  968 (88.9)  997 (89.9)
* ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, PCI percutaneous coronary interven-
tion, and TIMI Thrombolysis in Myocardial Infarction.
† P<0.05 for the between-group comparisons in this category.
‡ The routine use of a glycoprotein IIb/IIIa inhibitor in the bivalirudin group was a deviation from the protocol.
§ Data are provided for patients who were eligible for bailout use of a glycoprotein IIb/IIIa inhibitor (i.e., those who did 
not receive the drug routinely).
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the Supplementary Appendix). Of these patients, 
1102 were randomly assigned to the bivalirudin 
group and 1116 to the control group with op-
tional receipt of a glycoprotein IIb/IIIa inhibitor. 
Of the 2218 patients who provided initial 
abridged informed consent, 2198 provided for-
mal written informed consent (1089 in the bivali-
rudin group and 1109 in the control group); 
these patients were included in the intention-to-
treat population. The baseline characteristics of 
patients were generally well matched between 
the two groups, although there were higher rates 
of diabetes and previous myocardial infarction in 
the control group (Table 1).
Treatments and Procedures
Treatments and procedures are summarized in 
Table 2. The median time between study-drug 
initiation and coronary angiography was 50 min-
utes. There was similar use of femoral arterial 
access and radial access. More than 90% of pa-
tients who underwent primary PCI received 
stents, with more than half receiving drug-eluting 
stents. Aspiration thrombectomy was performed 
in nearly one third of patients.
Most patients in the control group received 
unfractionated heparin (median dose, 61 IU per 
kilogram [interquartile range, 55 to 71]), with 
only a small proportion receiving enoxaparin 
(median dose, 50 IU per kilogram [interquartile 
range, 46 to 56]) (Table 2). Glycoprotein IIb/IIIa 
inhibitors were used in 11.5% of patients in the 
bivalirudin group and 69.1% in the control group. 
After PCI, 850 of 914 patients (93.0%) in the 
bivalirudin group received a prolonged (2 hours 
or longer) infusion of bivalirudin, with 191 of 
850 patients (22.5%) receiving the PCI dose and 
659 of 850 patients (77.5%) receiving the reduced 
dose of 0.25 mg per kilogram per hour. The 
median duration of bivalirudin infusion was 268 
minutes (interquartile range, 250 to 292).
Outcomes
The main trial outcomes are summarized in Ta-
ble 3 and shown in Figure 1, as well as in Figures 
S2, S3, and S4 in the Supplementary Appendix. 
The primary outcome occurred in 5.1% of the 
patients in the bivalirudin group and 8.5% in the 
control group with optional use of glycoprotein 
IIb/IIIa inhibitors (relative risk in the bivalirudin 
group, 0.60; 95% confidence interval [CI], 0.43 to 
0.82; P = 0.001). The rate of occurrence of the 
principal secondary outcome was 6.6% in the bi-
valirudin group and 9.2% in the control group 
(relative risk, 0.72; 95% CI, 0.54 to 0.96; P = 0.02).
There was no significant difference in rates 
of death, regardless of whether the cause was 
cardiac or noncardiac. There was a lower rate of 
non-CABG major bleeding in the bivalirudin 
group than in the control group (2.6% vs. 6.0%; 
relative risk, 0.43; 95% CI, 0.28 to 0.66; P<0.001), 
as well as lower rates of TIMI major or minor 
bleeding and any GUSTO bleeding (Table 3). 
Bivalirudin also reduced the rate of transfusion. 
Detailed information on individual types of 
bleeding events is provided in Table S1 in the 
Supplementary Appendix. There was no signifi-
cant difference in rates of reinfarction, although 
the episodes were numerically more frequent in 
the bivalirudin group than in the control group.
Stent thrombosis was more frequent in the 
bivalirudin group than in the control group 
(1.6% vs. 0.5%; relative risk, 2.89; 95% CI, 1.14 
to 7.29; P = 0.02); the difference was accounted 
for by stent thrombosis that occurred within 24 
hours (Table 3), with no significant difference in 
rates of subacute stent thrombosis (occurring 
within 30 days). The median time to acute stent 
thrombosis in the bivalirudin group was 2.3 
hours (interquartile range, 1.8 to 2.8). None of 
the acute stent thromboses were fatal. One death 
was attributed to subacute stent thrombosis in 
the control group. Of the patients who had stent 
thrombosis, 65.2% had reinfarction and 100% 
had ischemia-driven revascularization associated 
with the stent thrombosis.
Sensitivity and Subgroup Analyses
Sensitivity analyses for the primary and principal 
secondary composite outcomes were performed 
in both the per-protocol population (all patients 
who underwent randomization, provided in-
formed consent, received the randomized treat-
ment, and underwent angiography) and the PCI 
population (all patients who underwent primary 
PCI) (Table S2 in the Supplementary Appendix). 
The results of these analyses were consistent 
with those in the intention-to-treat analysis.
An analysis of the effect of bivalirudin in 12 
prespecified subgroups showed results that were 
consistent with those in the overall intention-to-
treat analysis with respect to the primary out-
come (Fig. 2), principal secondary outcomes (Fig. 
S5 in the Supplementary Appendix), and non-
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Table 3. Clinical Outcomes at 30 Days.*
Outcome
Bivalirudin
(N = 1089)
Control
(N = 1109)
Relative Risk 
(95% CI) P Value
no. (%)
Death or non-CABG major bleeding: primary outcome 55 (5.1) 94 (8.5) 0.60 (0.43–0.82) 0.001
Death, reinfarction, or non-CABG major bleeding: principal 
secondary outcome
72 (6.6) 102 (9.2) 0.72 (0.54–0.96) 0.02
Death 32 (2.9) 34 (3.1) 0.96 (0.60–1.54) 0.86
Cardiac cause 27 (2.5) 33 (3.0) 0.83 (0.50–1.38) 0.48
Noncardiac cause 5 (0.5) 1 (0.1) 5.09 (0.60–43.51) 0.12
Non-CABG bleeding
Major 28 (2.6) 67 (6.0) 0.43 (0.28–0.66) <0.001
Major or minor 85 (7.8) 149 (13.4) 0.58 (0.45–0.75) <0.001
TIMI definition
Major 14 (1.3) 23 (2.1) 0.62 (0.32–1.20) 0.15
Major or minor 85 (7.8) 146 (13.2) 0.59 (0.46–0.76) <0.001
GUSTO definition
Any 85 (7.8) 148 (13.3) 0.58 (0.45–0.75) <0.001
Severe or life-threatening 6 (0.6) 10 (0.9) 0.61 (0.22–1.68) 0.33
Severe or life-threatening or moderate 14 (1.3)  26 (2.3) 0.55 (0.29–1.04) 0.06
Blood transfusion 23 (2.1) 43 (3.9) 0.54 (0.33–0.90) 0.02
Reinfarction
Any 19 (1.7) 10 (0.9) 1.93 (0.90–4.14) 0.08
Q-wave 3 (0.3) 2 (0.2) 1.53 (0.26–9.12) 0.68
Non–Q-wave 16 (1.5) 8 (0.7) 2.04 (0.88–4.74) 0.09
Stent thrombosis†
Definite 17 (1.6) 6 (0.5) 2.89 (1.14–7.29) 0.02
≤24 hr 12 (1.1) 2 (0.2) 6.11 (1.37–27.24) 0.007
>24 hr to 30 days 5 (0.5) 4 (0.4) 1.27 (0.34–4.73) 0.75
Probable 0 0 NA NA
Major adverse cardiovascular events: death, reinfarction, ischemia-
driven revascularization, or stroke‡
65 (6.0) 61 (5.5) 1.09 (0.77–1.52) 0.64
Net adverse clinical events: death, reinfarction, ischemia-driven 
revascularization, stroke,‡ or non-CABG major bleeding§
85 (7.8) 118 (10.6) 0.73 (0.56–0.96) 0.02
Ischemia-driven revascularization 24 (2.2) 17 (1.5) 1.44 (0.78–2.66) 0.25
Reinfarction, ischemia-driven revascularization, or stent thrombosis 29 (2.7) 21 (1.9) 1.41 (0.81–2.45) 0.23
Stroke
Any‡ 6 (0.6) 11 (1.0) 0.56 (0.21–1.50) 0.24
Ischemic 6 (0.6) 9 (0.8) 0.68 (0.24–1.90) 0.46
Hemorrhagic 0 2 (0.2) NA 0.50
Acquired thrombocytopenia¶ 7 (0.7) 14 (1.4) 0.50 (0.20–1.24) 0.13
* GUSTO denotes Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries, and NA not applicable.
† Stent thrombosis was defined according to the criteria of the Academic Research Consortium.9
‡ Stroke includes ischemic and hemorrhagic events and those of unknown cause.
§ Net adverse clinical events were a composite of major adverse cardiovascular events and non-CABG major bleeding.
¶ A total of 996 patients in the bivalirudin group and 999 patients in the control group were evaluated for acquired thrombocytopenia.
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CABG major bleeding (Fig. S6 in the Supplemen-
tary Appendix). In these analyses, there were no 
significant interactions with baseline or proce-
dural variables, including the arterial-access site 
and type of P2Y12 inhibitor that was adminis-
tered. The effect of bivalirudin on the primary 
outcome appeared to be consistent regardless of 
whether patients in the control group received 
routine glycoprotein IIb/IIIa inhibitors (5.1% vs. 
7.6%; relative risk, 0.67; 95% CI, 0.46 to 0.97; 
P = 0.03) or did not receive such therapy (5.1% vs. 
9.8%; relative risk, 0.52; 95% CI, 0.35 to 0.75; 
P<0.001).
Discussion
In our study, prehospital initiation of bivalirudin, 
as compared with heparin with optional use of 
glycoprotein IIb/IIIa inhibitors, reduced the pri-
mary composite outcome of death or major 
bleeding at 30 days in patients with STEMI who 
were being transported for primary PCI. The sec-
ondary composite outcome of death, reinfarc-
tion, and major bleeding at 30 days was also re-
duced with bivalirudin. These benefits, which 
were consistent across subgroups, stemmed from 
substantial reductions in major bleeding. How-
ever, the risk of acute stent thrombosis was high-
er in the bivalirudin group.
The HORIZONS-AMI trial showed that during 
primary PCI for STEMI, bivalirudin alone was 
superior to heparin plus a glycoprotein IIb/IIIa 
inhibitor, with a marked reduction in bleeding at 
30 days.3 There was also a reduction in the rate of 
death from cardiac causes and any cause, which 
was sustained for up to 3 years.4,12 Given evolving 
changes in clinical practice, our study was de-
signed to determine whether these benefits of 
bivalirudin would persist in the contemporary 
setting. Important changes in this regard include 
prehospital initiation of intravenous anticoagula-
tion,13,14 increasing use of radial access for cath-
eterization and PCI,5,15,16 reduced use of glycopro-
tein IIb/IIIa inhibitors during primary PCI,1,2,17 
and the advent of the novel P2Y12 inhibitors 
(ticagrelor and prasugrel6,7).
In our study, the initiation of bivalirudin in 
the prehospital setting achieved substantial re-
ductions in bleeding, regardless of the choice for 
arterial access or P2Y12 inhibitor and even when 
the use of glycoprotein IIb/IIIa inhibitors was 
optional. However, at 30 days, we did not find 
the benefit of bivalirudin in reduced rates of 
death from cardiac and other causes that were 
seen in the HORIZONS-AMI trial. Data are cur-
rently being collected on 1-year mortality as a 
prespecified end point.
In the HORIZONS-AMI trial, there was an 
increased risk of acute stent thrombosis among 
patients receiving bivalirudin. The discontinua-
tion of bivalirudin at the end of PCI and before 
the onset of the antiplatelet effect of oral P2Y12 
inhibitors may have created a vulnerable window 
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Figure 1. Kaplan–Meier Curves of Study Outcomes.
Shown are the rates of events for the primary composite outcome (death or 
major bleeding not associated with coronary-artery bypass grafting [CABG]) 
(Panel A) and the principal secondary outcome (a composite of death, re-
infarction, or non-CABG major bleeding) (Panel B) at 30 days. The inset 
graph shows a more detailed version of the overall graph.
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for stent thrombosis. In contrast, in the heparin 
group, acute stent thrombosis was either mini-
mized or delayed by the prolonged infusion of 
glycoprotein IIb/IIIa inhibitors.18,19 In our study, 
there was also a higher risk of acute stent 
thrombosis in the bivalirudin group, which sug-
gests that neither a prolonged, reduced-dose in-
fusion of bivalirudin nor the use of the new oral 
P2Y12 inhibitors was sufficient to address this 
risk. Given the delayed onset of the antiplatelet 
effect of the oral P2Y12 inhibitors in patients 
with STEMI,20 avoiding the occurrence of stent 
0.5 1.0 5.0
Control
Better
Bivalirudin
Better
All patients
Age
>65 yr
≤65 yr
Sex
Male
Female
Diabetes
Yes
No
Arterial-access site
Radial
Femoral
Vessels with stenosis >50%
1 vessel
≥2 vessels
Stent type
At least one drug-eluting stent
All bare-metal stents
Killip class
I
II to IV
P2Y12 inhibitor loading therapy
Clopidogrel
Prasugrel
Ticagrelor
P2Y12 inhibitor maintenance therapy
Clopidogrel
Prasugrel
Ticagrelor
Drug initiation to angiography
<50 min
≥50 min
Baseline creatinine clearance
≤60 ml/min
>60 ml/min
Target vessel
Left anterior descending (LAD)
No LAD
Bivalirudin
(N=1089) Relative Risk (95% CI)
Control
(N=1109)Subgroup
0.60 (0.43–0.82)
0.50 (0.31–0.79)
0.71 (0.45–1.11)
0.67 (0.42–1.08)
0.53 (0.32–0.86)
0.34 (0.15–0.78)
0.78 (0.41–1.49)
0.73 (0.42–1.29)
0.53 (0.26–1.08)
0.55(0.38–0.80)
0.89 (0.44–1.77)
0.68 (0.42–1.12)
0.69 (0.37–1.29)
0.79 (0.47–1.31)
0.57 (0.36–0.90)
0.52 (0.29–0.93)
0.60 (0.33–1.10)
0.55 (0.36–0.84)
0.55 (0.33–0.92)
0.54 (0.31–0.94)
0.65 (0.42–1.01)
0.61 (0.40–0.94)
0.60 (0.35–1.03)
0.69 (0.41–1.16)
0.53(0.35–0.80)
0.47 (0.26–0.85)
0.1
0.70 (0.48–1.03)
P Value for
Interaction
  55/1089 (5.1)
39/394 (9.9)
16/695 (2.3)
32/814 (3.9)
23/275 (8.4)
12/127 (9.4)
40/946 (4.2)
20/510 (3.9)
31/558 (5.6)
19/591 (3.2)
28/407 (6.9)
22/538 (4.1)
16/330 (4.8)
32/919 (3.5)
14/77 (18.2)
25/524 (4.8)
16/323 (5.0)
11/201 (5.5)
19/377 (5.0)
16/321 (5.0)
  7/257 (2.7)
23/514 (4.5)
27/549 (4.9)
  21/147 (14.3)
28/854 (3.3)
30/425 (7.1)
26/664 (3.8)
  94/1109 (8.5)
  61/434 (14.1)
33/675 (4.9)
64/861 (7.4)
  30/248 (12.1)
18/169 (10.7)
71/926 (7.7)
33/502 (6.6)
53/582 (9.1)
33/556 (5.9)
  49/462 (10.6)
39/529 (7.4)
27/336 (8.0)
59/931 (6.3)
24/69 (34.8)
38/545 (7.0)
22/306 (7.2)
  21/205 (10.2)
28/407 (6.9)
19/298 (6.4)
21/259 (8.1)
42/495 (8.5)
42/576 (7.3)
  30/165 (18.2)
48/833 (5.8)
42/423 (9.9)
52/686 (7.6)
0.31
0.47
0.26
0.97
0.66
0.84
0.58
0.82
0.24
0.48
0.44
0.30
no. of events/total no. (%)
Figure 2. Subgroup Analyses of the Primary Composite Outcome.
Shown are the rates of the primary composite outcome (death or major bleeding not associated with coronary-artery bypass grafting at 
30 days) in subgroups of the 2198 study patients with ST-segment elevation myocardial infarction who received either bivalirudin or un-
fractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors (control group).
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thrombosis may require more potent and rapidly 
effective antithrombotic agents, such as intrave-
nous antiplatelet drugs.21,22 Our study showed a 
nonsignificant increase in rates of reinfarction 
and ischemia-driven revascularization in the bi-
valirudin group, which appeared to be driven 
primarily by the increased rate of acute stent 
thrombosis. However, our study was not powered 
to examine these outcomes separately.
Some limitations of our study should be taken 
into consideration. The primary composite out-
come was changed in order to reduce the sample 
size as a consequence of slow enrollment. An 
open-label design was implemented because of 
the logistic impracticality of a double-blind de-
sign in the context of emergency transport for 
primary PCI in a multinational trial. To minimize 
reporting bias that can be associated with an 
open-label design, events were adjudicated blind-
ly by an independent clinical-events committee 
that used standardized end-point definitions. The 
trial was not powered to examine 30-day mortal-
ity and its cardiac and noncardiac subsets. Al-
though the use of anticoagulation before cathe-
terization was a notable feature of our study, 
the trial was neither designed nor intended to 
compare such use with use in the catheterization 
laboratory. Finally, although the trial allowed for 
the use of either unfractionated heparin or 
enoxaparin, too few patients received the latter 
(which is an accepted option in Europe1) to reli-
ably test the consistency of the benefit among 
types of heparin.
In conclusion, in patients with STEMI who 
were being transported for primary PCI, bivaliru-
din, as compared with heparin with optional use 
of glycoprotein IIb/IIIa inhibitors, reduced 30-day 
rates of the primary and principal secondary out-
comes, through a reduction in major bleeding, 
with higher rates of acute stent thrombosis.
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